PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23515587-10	2014	EGCG treatment also counteracted the activity of TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappaB pathways.	epigallocatechin gallate	0-4	forkhead box O1	Rattus norvegicus	69-74	
23515587-12	2014	CONCLUSIONS: Epigallocatechin gallate (EGCG) reduced the severity of liver injury in an experimental model of NAFLD associated with lower concentration of pro-fibrogenic, oxidative stress, and pro-inflammatory mediators partly through modulating the activities of TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappaB pathways.	epigallocatechin gallate	13-37	forkhead box O1	Rattus norvegicus	284-289	
23515587-12	2014	CONCLUSIONS: Epigallocatechin gallate (EGCG) reduced the severity of liver injury in an experimental model of NAFLD associated with lower concentration of pro-fibrogenic, oxidative stress, and pro-inflammatory mediators partly through modulating the activities of TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappaB pathways.	epigallocatechin gallate	39-43	forkhead box O1	Rattus norvegicus	284-289